[1] Seglen PO. Preparation of rat liver cells.3. Enzymatic require?
ments for tissue dispersion[J].Exp Cell Res,1973,82(2):
391-398.
[2] Nanavaty MA, Johar K, Sivasankaran MA,etal.Effectoftry?
pan blue staining on the density and viability of lens epithelialcells in white cataract[J].J Cataract Refract Surg,2006,32
(9):1483-1488.
[3] 曾民德.脂肪性肝病的氧应激及其治疗对策[J].国外医学:消
化系疾病分册,2005,25(5):263-266.
[4] Xia XJ, Chen Z, Yu JQ. ROS mediate brassinosteroids-in?
duced plant stress responses[J].Plant Signal Behav,2010,5
(5):532-534.
[5] Qureshi K, Abrams GA. Metabolic liver disease of obesity and
role of adipose tissue in the pathogenesis of nonalcoholic fatty
liver disease[J].World J Gastroenterol,2007,13(26):3540-3553.
[6] 钟岚,范建高,李为真,等.非酒精性脂肪性肝炎发病机制的实验
研究[J].中华消化杂志,2006,26(5):481-484.
[7] 陆伦根,曾民德.改善胰岛素抵抗在非酒精性脂肪性肝病防治中
的作用[J].中华肝脏病杂志,2003,11(2):113.
[8] Pessayre D. Role of mitochondria in non-alcoholic fatty liver
disease[J].Gastroenterolhepatol,2007,22(1):22-27.
[9] VajtaG,DivaldA,PakuS,etal.Fattydegenerationincultured
hepatocyte. A new experimental model[J].Virchows Arch B
CellPatholInciMolPathol,1986,52(2):177-184.
[10]Mehta JL, Hu B, Chen J,et al. Rosiglitazone inhibits Lox-1
expression in human coronary artery endothelial cells by reduc?
ing intracellular superoxide radical generation [J].Arterio?
sclerThromb Vasc Biol,2006,23(12):2203-2208.
[11]戴林,邓彬,白成,等.吡格列酮对大鼠非酒精性脂肪肝炎干预的
实验研究[J].胃肠病学和肝病学杂志,2004,13(5):482-484.
[12]Musso G, Gambino R, Cassader M,et al. A meta-analysis of
randomized trials for the treatment of nonalcoholic fatty liver
disease[J].Hepatology,2010,52(1):79-104.
[13]Pasumarthy L, Srour J. Nonalcoholic steatohepatitis:a review
of the literature and updates in management[J].South Med
J,2010,103(6):547-550.
[14]Sanyal AJ, Chalasani N, Kowdiey KV,et al. Pioglitazone, vi?
tamin E,or placebo for nonalcoholic steatohepatitis [J].N
EnglJ Med,2010,362(7):1675-1685.
[15]中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂
肪性肝病诊疗指南.中华肝脏病杂志,2006,14(4):161-163.